Keynote B21 - Pembrolizumab in High-Risk Endometrial Cancer (Video Explainer)
Video Explaining B-21 Trial
Endometrial Cancer
ATtend Trial: Atezolizumab + chemotherapy for advanced or recurrent endometrial cancer
Atezolizumab with chemotherapy improved progression-free survival in advanced or recurrent endometrial carcinoma, especially in dMMR tumors, though overall survival hasn't shown significant benefit yet. In the pMMR population, no significant PFS or OS benefit was observed; OS benefit is minimal.
SIENDO Trial: Selinexor in TP53wt Advanced or Recurrent Endometrial Cancer
GOG 238: Radiation With or Without Cisplatin in Endometrial Cancer
Adding cisplatin to radiation therapy does not improve PFS or OS for patients with localized recurrences of endometrial cancer and results in higher toxicity rates. Radiation therapy alone remains an effective treatment for these patients.
ENGOT-EN5/GOG-3055/SIENDO: Selinexor in Endometrial Cancer (Phase II)
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced
GOG 3007: Megace Tamoxifen vs Letrozole Everolimus
Both treatment arms demonstrated clinically meaningful efficacy in patients with recurrent endometrial carcinoma. The combination of everolimus and letrozole showed a non-significant trend toward improved survival outcomes compared to standard hormonal therapy.
TOTEM Trial: Intensive vs. Minimalist Follow-up in Endometrial Cancer
An intensive follow-up in patients treated for endometrial cancer does not improve overall survival or relapse detection significantly compared to a minimalist approach.
Adjuvant Treatment of Endometrial Cancer - Part 1
GOG 122: Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma
AP chemotherapy significantly improved both progression-free and overall survival compared to WAI in patients with advanced endometrial carcinoma, although it was associated with greater acute toxicity.
PORTEC 1: EBRT vs. Observation in Endometrial Cancer
While postoperative radiotherapy reduces locoregional recurrence, it does not impact overall survival and increases treatment-related morbidity.